A Novel Model of Cancer-Induced Peripheral Neuropathy and the Role of TRPA1 in Pain Transduction
Ahmad Maqboul, Bakheet Elsadek

TL;DR
This study introduces a new rat model for cancer-induced peripheral neuropathy, highlighting the role of TRPA1 and CGRP in pain mechanisms and demonstrating that TRPA1 antagonists can temporarily alleviate cold allodynia.
Contribution
The paper presents a novel model of cancer-induced neuropathy and investigates the specific involvement of TRPA1 and CGRP in pain transduction, providing new insights into potential therapeutic targets.
Findings
TRPA1 and CGRP are overexpressed in the model.
TRPA1 antagonists temporarily reverse cold allodynia.
TRPA1 expression peaks at day 14 post-inoculation.
Abstract
Background. Models of cancer-induced neuropathy are designed by injecting cancer cells near the peripheral nerves. The interference of tissue-resident immune cells does not allow a direct contact with nerve fibres which affects the tumor microenvironment and the invasion process. Methods. Anaplastic tumor-1 (AT-1) cells were inoculated within the sciatic nerves (SNs) of male Copenhagen rats. Lumbar dorsal root ganglia (DRGs) and the SNs were collected on days 3, 7, 14, and 21. SN tissues were examined for morphological changes and DRG tissues for immunofluorescence, electrophoretic tendency, and mRNA quantification. Hypersensitivities to cold, mechanical, and thermal stimuli were determined. HC-030031, a selective TRPA1 antagonist, was used to treat cold allodynia. Results. Nociception thresholds were identified on day 6. Immunofluorescent micrographs showed overexpression of TRPA1 on…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
